Collegium Pharmaceutical, Inc.
COLL
$35.81
$1.012.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.92% | 31.42% | 29.41% | 22.66% | 21.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.92% | 31.42% | 29.41% | 22.66% | 21.51% |
| Cost of Revenue | 1.79% | 6.15% | 11.20% | 13.37% | 17.58% |
| Gross Profit | 14.62% | 35.14% | 32.31% | 24.05% | 22.13% |
| SG&A Expenses | 8.46% | 55.82% | 80.47% | 82.04% | 78.03% |
| Depreciation & Amortization | 0.00% | 35.96% | 60.72% | 60.71% | 60.72% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.90% | 38.16% | 58.69% | 60.69% | 57.10% |
| Operating Income | 41.52% | 19.01% | -25.51% | -50.73% | -29.31% |
| Income Before Tax | 68.14% | 178.79% | -41.49% | -91.48% | -63.03% |
| Income Tax Expenses | 155.08% | 91.02% | -46.88% | -92.09% | -67.96% |
| Earnings from Continuing Operations | 35.31% | 237.51% | -38.88% | -91.28% | -60.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.31% | 237.51% | -38.88% | -91.28% | -60.75% |
| EBIT | 41.52% | 19.01% | -25.51% | -50.73% | -29.31% |
| EBITDA | 17.97% | 25.99% | 9.60% | -4.67% | 3.06% |
| EPS Basic | 37.13% | 244.85% | -37.68% | -91.13% | -60.48% |
| Normalized Basic EPS | 104.69% | 19.96% | -49.31% | -83.86% | -50.92% |
| EPS Diluted | 31.48% | 213.22% | -34.00% | -90.11% | -61.84% |
| Normalized Diluted EPS | 102.17% | 19.54% | -48.61% | -79.98% | -49.84% |
| Average Basic Shares Outstanding | -1.33% | -2.13% | -1.92% | -1.65% | -0.69% |
| Average Diluted Shares Outstanding | -0.08% | -1.80% | -3.24% | -20.75% | -2.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |